CN118059206A - Antidepressant traditional Chinese medicine composition and preparation method and application thereof - Google Patents
Antidepressant traditional Chinese medicine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN118059206A CN118059206A CN202410210087.9A CN202410210087A CN118059206A CN 118059206 A CN118059206 A CN 118059206A CN 202410210087 A CN202410210087 A CN 202410210087A CN 118059206 A CN118059206 A CN 118059206A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- group
- glue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域Technical Field
本发明属于中药领域,具体涉及一种抗抑郁的中药组合物及其制备方法和应用。The invention belongs to the field of traditional Chinese medicine, and particularly relates to an antidepressant traditional Chinese medicine composition and a preparation method and application thereof.
背景技术Background Art
抑郁症已成为现代社会的常见病和多发病,其发病率还在不断升高。病症以情感低落、兴趣减退、思维迟缓以及言语与动作减少为特征,重症抑郁患者有厌世或自杀的念头,这类疾病会给患者及其家属带来很大的痛苦。现代医学研究认为抑郁症的病因复杂,其发病可能涉及到神经递质紊乱、脑源性神经营养因子缺乏、下丘脑-垂体-肾上腺轴失调、炎症反应、能量代谢异常及神经元再生障碍等多种机制。目前临床上治疗抑郁症的药物主要包括5-HT重摄取抑制剂(SSRIs)、NE重摄取抑制剂(NRIs)、5-HT/NE双重重摄取抑制剂(SNRIs)、三环类抗抑郁药物(TCAs)及单胺氧化酶抑制剂(MAOIs)等。尽管这类药物具有一定的临床疗效,但存在起效慢,作用谱窄,副作用大,停药后易复发等缺陷。Depression has become a common and frequently occurring disease in modern society, and its incidence is still increasing. Symptoms are characterized by low emotions, loss of interest, slow thinking, and reduced speech and movement. Patients with severe depression have thoughts of world-weariness or suicide. Such diseases can cause great pain to patients and their families. Modern medical research believes that the etiology of depression is complex, and its onset may involve multiple mechanisms such as neurotransmitter disorders, brain-derived neurotrophic factor deficiency, hypothalamic-pituitary-adrenal axis disorders, inflammatory reactions, abnormal energy metabolism, and neuronal regeneration disorders. At present, the main drugs used in clinical treatment of depression include 5-HT reuptake inhibitors (SSRIs), NE reuptake inhibitors (NRIs), 5-HT/NE dual reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Although these drugs have certain clinical efficacy, they have defects such as slow onset, narrow spectrum of action, large side effects, and easy relapse after discontinuation of medication.
近年来,随着中医药现代化研究的发展,中药在治疗抑郁症方面显示出强大的优势。中药具有“多成分、多靶点、多途径”作用的特点,且安全、副作用小,因此在临床上将中药用于治疗抑郁症的顺应性得到了极大的提高。现有技术中已有不少用于治疗抑郁症的中药组合物,如:In recent years, with the development of modern research on traditional Chinese medicine, traditional Chinese medicine has shown strong advantages in the treatment of depression. Traditional Chinese medicine has the characteristics of "multiple components, multiple targets, and multiple pathways", and is safe and has few side effects. Therefore, the compliance of using traditional Chinese medicine to treat depression in clinical practice has been greatly improved. There are already many traditional Chinese medicine compositions for the treatment of depression in the prior art, such as:
专利CN102233071B公开一种用于治疗抑郁症的中药组合物及其制备方法,该中药组合物由下述质量份的原料制成:人参1-6份、远志1-5份、石菖蒲1-5份、茯苓1-6份、巴戟天1-6份、柴胡1-5份、枳实1-5份、赤芍1-6份和甘草1-5份。该中药组合物具有益气养心安神、理气疏肝、活血解郁的功效。Patent CN102233071B discloses a Chinese medicine composition for treating depression and a preparation method thereof, wherein the Chinese medicine composition is made of the following raw materials in parts by weight: 1-6 parts of ginseng, 1-5 parts of polygala, 1-5 parts of calamus, 1-6 parts of tuckahoe, 1-6 parts of morinda officinalis, 1-5 parts of bupleurum, 1-5 parts of immature bitter orange, 1-6 parts of red peony root and 1-5 parts of liquorice. The Chinese medicine composition has the effects of invigorating qi, nourishing the heart and calming the mind, regulating qi and soothing the liver, and promoting blood circulation and relieving depression.
专利CN115429864B公开一种用于治疗抑郁症的中药组合物,包含下列重量份配比的中药原料:柴胡0.5~6份、贯叶金丝桃0.5~6份、白芍1~5份、郁金0.8~5份、佛手0.8~5份、太子参1~6份、白术1~5份、茯神0.5~4份、酸枣仁0.8~5份、缬草1~5份、合欢皮1~6份。上述药味合用,疏肝理气、健脾养心、安神解郁,用于肝郁脾虚、心神失养所致的轻、中度抑郁症。Patent CN115429864B discloses a Chinese medicine composition for treating depression, comprising the following Chinese medicine raw materials in weight proportions: 0.5-6 parts of bupleurum, 0.5-6 parts of Hypericum perforatum, 1-5 parts of white peony root, 0.8-5 parts of curcuma, 0.8-5 parts of citron, 1-6 parts of Pseudostellariae Radix, 1-5 parts of Atractylodes macrocephala, 0.5-4 parts of Poria, 0.8-5 parts of Ziziphus jujuba seeds, 1-5 parts of valerian, and 1-6 parts of Albizzia julibrissin. The above medicinal flavors are used together to soothe the liver and regulate qi, strengthen the spleen and nourish the heart, calm the mind and relieve depression, and are used for mild and moderate depression caused by liver depression, spleen deficiency, and mental malnutrition.
然而现有的中药组合物多是以肝论治抑郁症,普遍存在因阳气不足,温煦鼓动无力,气机流动不畅,阴阳失衡而致治疗效果不够理想的缺陷。因此仍需要从配方上深入研究以使得中药组合物的药效更佳、更可靠,达到标本兼治的效果。However, most of the existing Chinese medicine compositions treat depression based on the liver, and generally have the disadvantage of insufficient Yang Qi, weak warming and agitation, poor Qi flow, and imbalance of Yin and Yang, which leads to unsatisfactory treatment effects. Therefore, in-depth research on the formula is still needed to make the Chinese medicine composition more effective and reliable, so as to achieve the effect of treating both the symptoms and the root cause.
发明内容Summary of the invention
根据本发明的第一个方面,提供了一种抗抑郁的中药组合物,以质量份计其原料组成包括:附子55-65份、干姜55-65份、甘草85-95份、桂枝85-95份、白芍85-95份、牡蛎290-310份、山萸肉85-95份、乌梅40-55份、茯神145-155份、酸枣仁145-155份、大枣85-95份、山药145-155份、巴戟天55-65份、麦冬85-95份、砂仁25-35份、沉香25-35份、肉桂25-35份、黄精115-125份、龟甲胶10-20份、阿胶10-20份、鹿角胶10-20份。According to a first aspect of the present invention, an antidepressant traditional Chinese medicine composition is provided, wherein the raw materials thereof comprise, by weight, 55-65 parts of aconite root, 55-65 parts of dried ginger, 85-95 parts of liquorice, 85-95 parts of cinnamon twig, 85-95 parts of white peony root, 290-310 parts of oyster, 85-95 parts of cornus fruit, 40-55 parts of ebony, 145-155 parts of poria, 145-155 parts of spiny jujube seeds, 85-95 parts of jujube, 145-155 parts of yam, 55-65 parts of Morinda officinalis, 85-95 parts of ophiopogon, 25-35 parts of amomum, 25-35 parts of agarwood, 25-35 parts of cinnamon bark, 115-125 parts of polygonatum, 10-20 parts of tortoise shell glue, 10-20 parts of donkey-hide glue, and 10-20 parts of antler glue.
本发明针对郁证“阳虚气郁、阴阳失衡”的病机,以“温阳开郁、调和营卫”为治则,从温补阳气、调和营卫以开郁结,补血滋阴以平衡阴阳的角度着手,注重气血与脏腑之间的相互依存、相互统一的关系。本发明以温补阳气为基础,调和营卫为核心,辅以补血滋阴,平衡阴阳,从而能够有效温阳益气,调和阳表阴里,有效缓解抑郁症症状。The present invention targets the pathogenesis of depression syndrome "Yang deficiency, Qi stagnation, imbalance of Yin and Yang", takes "warming Yang to relieve depression, and harmonizing Ying and Wei" as the treatment principle, starts from the perspective of warming Yang, harmonizing Ying and Wei to relieve depression, and nourishing blood and Yin to balance Yin and Yang, and pays attention to the interdependence and mutual unity between Qi, blood and internal organs. The present invention is based on warming Yang, harmonizing Ying and Wei as the core, supplemented by nourishing blood and Yin, balancing Yin and Yang, so as to effectively warm Yang and replenish Qi, harmonize Yang surface and Yin interior, and effectively relieve the symptoms of depression.
本发明以桂枝、白芍为君药,调和营卫,交通阴阳。桂枝辛温,温从阳而扶卫,白芍酸寒,酸寒走阴而益营;以附子、干姜、巴载天、肉桂、沉香为臣药,温补脾肾、温阳潜阳,引火归元以助桂枝和卫,同时以牡蛎、山萸肉、乌梅、茯神、酸枣仁、麦冬为臣药,酸甘化阴、养血安神以助白芍益营;以大枣、山药、砂仁、黄精、龟甲胶、阿胶、鹿角胶为佐药,山药、大枣、砂仁相合,可以升腾脾胃生发之气而调和营卫,龟甲胶、阿胶、鹿角胶补益精血,益阳化阴;同时,砂仁、黄精、麦冬合用,补益心脾,补阴精血,益阳化阴,从而调和营卫、安神定志,增强了整方的调和营卫、益阳化阴的作用,达到补虚纠偏、平衡阴阳的目的;以甘草为使药,调和诸药,调和阳表阴里,气卫血营,并行而不悖,是刚柔相济以为和也。全方调和营卫,引导阳气昼出于阴,夜入于阴,引导气机升降有序,中土健运,心肾交通;营气充盛,滋养血脉,补养心气则心脉充盈、心神彰明、魂魄安定;卫气调达,则能传达脏腑神机,沟通表里内外;全方在补血滋阴基础上温阳开郁,升降有序,能够有效温阳益气,行气开郁,调和阳表阴里,切合抑郁症之病机,使神魂皆有所养,郁滞得解,可恢复脏腑功能的协调,纠正阴阳偏胜偏衰的病理现象,使之恢复到正常状态。本方尤其适用于阳虚抑郁人群、伴有注意力不集中、情绪低落、眠差疲倦者。The present invention uses cinnamon twig and white peony root as the main medicine to harmonize the Ying and Wei and to communicate yin and yang. Cinnamon twig is pungent and warm, warming from the yang and supporting the Wei, while white peony root is sour and cold, sour and cold going to the yin and benefiting the Ying; aconite, dried ginger, barberry, cinnamon bark, and agarwood are used as the ministerial medicines to warm and nourish the spleen and kidney, warm the yang and suppress the yang, and guide the fire back to the origin to help cinnamon twig and Wei, while oyster, cornus fruit, black plum, poria, spiny jujube seed, and ophiopogon are used as the ministerial medicines to sour and sweeten the yin, nourish the blood and calm the mind to help white peony root benefit the Ying; jujube, yam, amomum, polygonatum, tortoise shell glue, donkey-hide glue, and deer horn glue are used as adjuvants, and yam, jujube, and amomum are combined to Turtle shell glue, donkey-hide glue and deer antler glue can raise the generative Qi of the spleen and stomach and harmonize the Ying and Wei. Turtle shell glue, donkey-hide glue and deer antler glue can nourish the essence and blood, and benefit the Yang and transform the Yin. At the same time, Amomum villosum, Polygonatum sibiricum and Ophiopogon japonicus can be used together to nourish the heart and spleen, replenish the Yin essence and blood, and benefit the Yang and transform the Yin, thereby harmonizing the Ying and Wei, calming the mind and settling the mind, and enhancing the effect of the whole prescription in harmonizing the Ying and Wei, benefiting the Yang and transforming the Yin, so as to achieve the purpose of replenishing deficiency, correcting deviation and balancing Yin and Yang. Licorice is used as a guiding drug to harmonize all the drugs, harmonize the Yang surface and Yin interior, and make the Qi, Wei, blood and Ying run in parallel without conflict, which is the harmony of hardness and softness. The whole formula harmonizes the Ying and Wei, guides the Yang to come out of the Yin during the day and enter the Yin at night, guides the Qi to rise and fall in an orderly manner, strengthens the middle earth, and connects the heart and kidney; when the Ying Qi is full, it nourishes the blood vessels, nourishes the heart Qi, and the heart veins are full, the mind is clear, and the soul is stable; when the Wei Qi is well regulated, it can convey the spirit of the internal organs and communicate the inside and outside; the whole formula warms the Yang and relieves depression on the basis of nourishing the blood and Yin, and rises and falls in an orderly manner. It can effectively warm the Yang and replenish the Qi, promote the flow of Qi and relieve depression, harmonize the Yang surface and Yin, and fit the pathogenesis of depression, so that the spirit and soul are nourished, and the depression is resolved, and the coordination of the internal organs can be restored, and the pathological phenomenon of the partial dominance of Yin and Yang can be corrected to restore it to a normal state. This prescription is especially suitable for people with yang deficiency depression, accompanied by inattention, low mood, poor sleep and fatigue.
本发明的原料来源如下:The raw material sources of the present invention are as follows:
附子:毛茛科植物乌头(栽培品)的旁生块根(子根)。Aconite: The lateral tuberous root (sub-root) of the Ranunculaceae plant Aconitum (cultivated product).
干姜:姜科植物姜Zingiber oj-jicinale Rosc.的干燥根茎。Dried ginger: the dried rhizome of Zingiber oj-jicinale Rosc., a plant of the ginger family.
甘草:豆科甘草属植物甘草Glycyrrhiza uralensis Fisch.的根和根状茎。Licorice: The roots and rhizomes of Glycyrrhiza uralensis Fisch., a plant of the genus Glycyrrhiza in the legume family.
桂枝:樟科植物菌桂的细枝。Cinnamon twig: twig of the cinnamon plant of the Lauraceae family.
白芍:毛莨科植物芍药的根。White peony root: the root of the Paeonia lactiflora plant of the Ranunculaceae family.
牡蛎:牡蛎科动物近江牡蛎、长牡蛎或大连湾牡蛎等的贝壳。Oyster: The shell of the oyster family, such as the Omi oyster, the long oyster or the Dalian Bay oyster.
山萸肉:山茱萸科植物山茱萸Cornus officinalis Sieb.et Zucc.的干燥成熟果肉。Cornus officinalis: the dried mature pulp of Cornus officinalis Sieb.et Zucc., a plant of the Cornaceae family.
乌梅:蔷薇科植物梅Prunus mume(Sieb.)Sieb.etZuce.的干燥近成熟果实。Black plum: the dried, nearly ripe fruit of Prunus mume (Sieb.) Sieb. et Zuce., a plant of the Rosaceae family.
茯神:多孔菌科卧孔属植物茯苓(Poria cocos Schw.)Wolf的菌核中夹有松根的部分。Poria: The sclerotium of Poria cocos Schw. Wolf, a plant of the Polyporaceae family, contains parts of pine roots.
酸枣仁:鼠李科植物酸枣Ziziphus jujuba Mill.var.spinosa(Bunge)Hu exH.F.Chou的干燥成熟种子。Ziziphus jujuba kernel: the dried mature seeds of Ziziphus jujuba Mill.var.spinosa (Bunge)Hu exH.F.Chou, a plant of the Rhamnaceae family.
大枣:鼠李科枣属植物枣Ziziphus jujuba Mill.var.inermis(Bunge)Rehd.的干燥成熟果实。Jujube: the dried mature fruit of Ziziphus jujuba Mill.var.inermis (Bunge) Rehd., a plant of the Rhamnaceae family.
山药:薯蓣科植物薯蓣Dioscorea opposita Thunb.的根茎。淮山药指的是广东、江苏、安徽等地所产的山药。Chinese yam: the rhizome of Dioscorea opposita Thunb., a plant of the Dioscoreaceae family. Huai yam refers to the Chinese yam produced in Guangdong, Jiangsu, Anhui and other places.
巴戟天:茜草科植物巴戟天Morinda officinalis How的干燥根。Morinda officinalis: The dried root of Morinda officinalis How, a plant of the Rubiaceae family.
麦冬:百合科植物麦冬(沿阶草)的干燥块根。Ophiopogon japonicus: the dried tuberous root of Ophiopogon japonicus (Ophiopogon japonicus), a plant of the Liliaceae family.
砂仁:姜科草本植物阳春砂AmonumvillqsumLouv.或海南砂A.longiligulareT.L.Wu或缩砂A.xanthioidesWall.的成熟果实。Amomum villosum: the ripe fruit of the herbaceous plants Amomum villosum Louv., A. longiligulare T.L. Wu, or A. xanthioides Wall. of the Zingiberaceae family.
沉香:瑞香科乔木沉香AquilariaagallochaRoxb.及白木香A.sinensis(Lour.)Gilg含有树脂的木材。Agarwood: The resin-containing wood of the Thymelaeaceae trees Aquilaria agallocha Roxb. and Aquilaria sinensis (Lour.) Gilg.
肉桂:樟科植物箘桂树的树皮。Cinnamon: the bark of the cinnamon tree of the Lauraceae family.
黄精:百合科植物黄精的根茎。Polygonatum: The rhizome of Polygonatum sibiricum, a plant of the Liliaceae family.
龟甲胶:龟甲经水煎煮、浓缩制成的固体胶。Turtle shell glue: solid glue made by boiling and concentrating tortoise shells.
阿胶:马科动物驴Equus asinus L.及其他驴皮经煎煮浓缩制成的固体胶。Donkey-hide gelatin: a solid gelatin made by boiling and concentrating the skin of the donkey Equus asinus L. and other donkeys of the Equine family.
鹿角胶:鹿科动物梅花鹿或马鹿的角煎熬而成的胶块。Deer antler glue: a glue block made by boiling the antlers of the sika deer or red deer, which are animals of the Cervidae family.
在一些实施方式中,以质量份计其原料组成包括:附子60份、干姜60份、甘草90份、桂枝90份、白芍90份、牡蛎300份、山萸肉90份、乌梅45份、茯神150份、酸枣仁150份、大枣90份、山药150份、巴戟天60份、麦冬90份、砂仁30份、沉香30份、肉桂30份、黄精120份、龟甲胶15份、阿胶15份、鹿角胶15份。In some embodiments, the raw material composition, measured by mass, includes: 60 parts of aconite, 60 parts of dried ginger, 90 parts of licorice, 90 parts of cinnamon twig, 90 parts of white peony root, 300 parts of oyster, 90 parts of cornus, 45 parts of ebony, 150 parts of poria, 150 parts of spinach seed, 90 parts of jujube, 150 parts of yam, 60 parts of Morinda officinalis, 90 parts of Ophiopogon japonicus, 30 parts of Amomum villosum, 30 parts of agarwood, 30 parts of cinnamon, 120 parts of polygonatum, 15 parts of tortoise shell glue, 15 parts of donkey-hide gelatin, and 15 parts of deer antler glue.
在一些实施方式中,附子为熟附子。熟附子为附子的炮制品。In some embodiments, the aconite root is cooked aconite root, which is a processed product of aconite root.
在一些实施方式中,甘草为炙甘草。炙甘草为甘草的蜜炙炮制品。In some embodiments, the licorice is roasted licorice, which is a honey-roasted product of licorice.
在一些实施方式中,山萸肉为制山萸肉。制山萸肉为山萸肉的炮制品。In some embodiments, the Fructus Corni is processed Fructus Corni. Processed Fructus Corni is a processed product of Fructus Corni.
在一些实施方式中,还包括药学上可以接受的辅料。In some embodiments, pharmaceutically acceptable excipients are also included.
在一些实施方式中,辅料为缓释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、吸附载体、表面活性剂、润滑剂中的至少一种。In some embodiments, the auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant, and a lubricant.
在一些实施方式中,中药组合物的剂型为膏剂、汤剂、颗粒剂、散剂、片剂、丸剂或胶囊剂。In some embodiments, the dosage form of the Chinese medicine composition is ointment, decoction, granules, powder, tablet, pill or capsule.
根据本发明的第二个方面,提供了上述的中药组合物的制备方法,当中药组合物的剂型为膏剂时,其制备方法包括如下步骤:According to a second aspect of the present invention, a method for preparing the above-mentioned Chinese medicine composition is provided. When the dosage form of the Chinese medicine composition is an ointment, the preparation method comprises the following steps:
(1)将除了沉香、龟甲胶、阿胶、鹿角胶之外的原料药材加入10倍量的水中,浸泡1小时,然后煎煮2次,每次煎煮时间为煮沸后继续煎煮1.5小时,合并2次煎煮得到的煎煮液,过80目筛滤过,得到煎煮药液;(1) adding the raw medicinal materials except agarwood, tortoise shell glue, donkey-hide gelatin, and deer antler glue to 10 times the amount of water, soaking for 1 hour, and then decocting twice, each decoction time is continued for 1.5 hours after boiling, combining the decoctions obtained from the two decoctions, filtering through an 80-mesh sieve, and obtaining a decoction liquid;
(2)将步骤(1)得到的煎煮药液在70-90℃下加热浓缩至相对密度为1.30-1.35(室温)的第一清膏;(2) heating the decoction obtained in step (1) at 70-90° C. and concentrating it to a first clear paste having a relative density of 1.30-1.35 (at room temperature);
(3)将龟甲胶、阿胶和鹿角胶混合,加入阿胶的3倍量的水,然后升温至60-80℃进行加热烊化,烊化后再加入步骤(2)得到的第一清膏中,搅拌均匀,得到第二清膏;(3) Mix tortoise shell glue, donkey-hide gelatin and deer antler glue, add water three times the amount of donkey-hide gelatin, and then heat to 60-80° C. to melt, and then add to the first clear paste obtained in step (2) after melting, stir evenly, to obtain a second clear paste;
(4)将沉香过120目筛得到沉香粉末,将步骤(3)得到的第二清膏加热升温至60℃后,再加入沉香粉末,搅拌混合均匀,得到混合药物;(4) Passing agarwood through a 120-mesh sieve to obtain agarwood powder, heating the second clear paste obtained in step (3) to 60° C., adding the agarwood powder, stirring and mixing evenly to obtain a mixed medicine;
(5)向步骤(4)得到的混合药物中按照1:1的质量比加入中蜜,然后加热至60℃,搅拌均匀,得到相对密度为1.43-1.46(30℃)的成品膏;(5) adding medium honey to the mixed drug obtained in step (4) at a mass ratio of 1:1, then heating to 60° C. and stirring evenly to obtain a finished paste with a relative density of 1.43-1.46 (30° C.);
(6)将步骤(5)所得成品膏冷却至室温后进行罐装,灭菌,即得。(6) Cooling the finished paste obtained in step (5) to room temperature, canning and sterilizing the finished paste.
根据本发明的第三个方面,提供了上述的中药组合物在制备治疗抑郁症的药物中的应用。具体地,抑郁症为阳虚型抑郁症。According to a third aspect of the present invention, there is provided a use of the above-mentioned Chinese medicine composition in the preparation of a drug for treating depression. Specifically, the depression is yang deficiency type depression.
本发明的有益效果包括:The beneficial effects of the present invention include:
(1)动物实验表明,本发明的中药组合物可以有效改善抑郁症模型大鼠、小鼠的行为学表现,减少脑组织尼氏小体损伤,调节脑组织海马体p-TrkB/TrkB、p-AKT/AKT及p-CREB/CREB等多种蛋白表达,通过改善海马神经元可塑性来防治抑郁症。由此提示,本发明的中药组合物可以有效治疗抑郁症。(1) Animal experiments show that the Chinese medicine composition of the present invention can effectively improve the behavioral performance of depression model rats and mice, reduce the damage of Nissl bodies in brain tissue, regulate the expression of multiple proteins such as p-TrkB/TrkB, p-AKT/AKT and p-CREB/CREB in the hippocampus of brain tissue, and prevent and treat depression by improving the plasticity of hippocampal neurons. This suggests that the Chinese medicine composition of the present invention can effectively treat depression.
(2)临床应用本发明的中药组合物能迅速改善抑郁症患者持续的情绪低落、言语减少、精神及运动迟缓等症状,并能解除倦怠乏力,反应迟钝、记忆力减退、失眠等症状。(2) Clinical Application The Chinese medicine composition of the present invention can rapidly improve the persistent depression, decreased speech, mental and motor retardation and other symptoms of depression patients, and can relieve the symptoms of fatigue, slow reaction, memory loss, insomnia and other symptoms.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为实施例1制备的中药膏样品成分表征的正离子模式下基峰离子色谱图,注:3,4,5,8,10,11,12,13,14分别代表甘草苷、芍药苷、马前苷、熊果酸、白桦脂酸、耐斯糖、麦冬皂苷B、顺式肉桂醛和无水葡萄糖。Figure 1 is a base peak ion chromatogram under positive ion mode for characterization of the components of the Chinese medicine ointment sample prepared in Example 1. Note: 3, 4, 5, 8, 10, 11, 12, 13, 14 represent liquiritin, paeoniflorin, magiformin, ursolic acid, betulinic acid, nastrin, ophiopogon saponin B, cis-cinnamaldehyde and anhydrous glucose, respectively.
图2为实施例1制备的中药膏样品成分表征的负离子模式下基峰离子色谱图,注:1,2,6,7,9,15分别代表桂皮醛、6-姜酚、莫诺苷、枸橼酸、斯皮诺素和沉香四醇。Figure 2 is a base peak ion chromatogram under negative ion mode for characterization of the components of the traditional Chinese medicine ointment sample prepared in Example 1, Note: 1, 2, 6, 7, 9, 15 represent cinnamaldehyde, 6-gingerol, morroniside, citric acid, spinosin and agarwood tetraol, respectively.
图3为实施例1制备的中药膏中活性成分姜辣素的二级质谱图。FIG. 3 is a secondary mass spectrum of gingerol, an active ingredient in the traditional Chinese medicine paste prepared in Example 1.
图4为实施例1制备的中药膏中活性成分斯皮诺素的二级质谱图。FIG. 4 is a secondary mass spectrum of spinosin, an active ingredient in the traditional Chinese medicine ointment prepared in Example 1.
图5为实施例1制备的中药膏中活性成分沉香四醇的二级质谱图。FIG5 is a secondary mass spectrum of agarwood tetraol, an active ingredient in the traditional Chinese medicine ointment prepared in Example 1.
图6为实施例1制备的中药膏中活性成分芍药苷的二级质谱图。FIG6 is a secondary mass spectrum of paeoniflorin, an active ingredient in the traditional Chinese medicine ointment prepared in Example 1.
图7为动物实验一的中药膏对皮质酮诱导抑郁症小鼠模型体质量的影响结果,注:对照代表正常对照组、模型代表模型组、低代表低剂量中药膏组、中代表中剂量中药膏组、高代表高剂量中药膏组、阳代表阳性药组。Figure 7 shows the results of the effect of the Chinese herbal ointment on the body weight of the corticosterone-induced depression mouse model in animal experiment 1. Note: control represents the normal control group, model represents the model group, low represents the low-dose Chinese herbal ointment group, medium represents the medium-dose Chinese herbal ointment group, high represents the high-dose Chinese herbal ointment group, and positive represents the positive drug group.
图8为动物实验一的中药膏对皮质酮诱导抑郁症模型小鼠海马神经元的影响(20×),注:A:正常对照组;B:模型组;C:低剂量中药膏组;D:中剂量中药膏组;E:高剂量中药膏组;F:阳性药组。Figure 8 shows the effect of the Chinese medicine ointment in animal experiment 1 on the hippocampal neurons of mice with corticosterone-induced depression model (20×), Note: A: normal control group; B: model group; C: low-dose Chinese medicine ointment group; D: medium-dose Chinese medicine ointment group; E: high-dose Chinese medicine ointment group; F: positive drug group.
图9为动物实验一的小鼠海马组织中Trkb、CREB、BDNF和p-Akt蛋白表达条带图,注:图中,A:正常对照组;B:模型组;C:低剂量中药膏组;D:中剂量中药膏组;E:高剂量中药膏组;F:阳性药组。Figure 9 is a bar graph of Trkb, CREB, BDNF and p-Akt protein expression in the mouse hippocampus tissue of animal experiment 1. Note: In the figure, A: normal control group; B: model group; C: low-dose Chinese medicine ointment group; D: medium-dose Chinese medicine ointment group; E: high-dose Chinese medicine ointment group; F: positive drug group.
图10为动物实验二的各组对CUMS抑郁模型大鼠SPT(A)、NSF(B)和FST(C)的作用比较结果,注:*p<0.05表示差异显著。FIG. 10 is a comparison of the effects of each group in the animal experiment 2 on SPT (A), NSF (B) and FST (C) of CUMS depression model rats. Note: *p<0.05 indicates significant difference.
图11为动物实验二的各组大鼠海马区神经元细胞形态学变化(尼氏染色,20×),注:A:对照组、B:模型组、C:8.4g/kg SAO组、D:14g/kg SAO组、E:氟西汀组、F:14g/kg SAO+ANA-12组、G:ANA-12组。Figure 11 shows the morphological changes of neuronal cells in the hippocampus of each group of rats in animal experiment 2 (Nissl staining, 20×), Note: A: control group, B: model group, C: 8.4g/kg SAO group, D: 14g/kg SAO group, E: fluoxetine group, F: 14g/kg SAO+ANA-12 group, G: ANA-12 group.
图12为动物实验二的各组大鼠海马组织中BDNF、p-TrkB、p-AKT和p-CREB蛋白表达条带图,注:A:对照组、B:模型组、C:8.4g/kg SAO组、D:14g/kg SAO组、E:氟西汀组、F:14g/kg SAO+ANA-12组、G:ANA-12组。Figure 12 is a bar graph showing the expression of BDNF, p-TrkB, p-AKT and p-CREB proteins in the hippocampal tissue of each group of rats in Animal Experiment 2, Note: A: control group, B: model group, C: 8.4 g/kg SAO group, D: 14 g/kg SAO group, E: fluoxetine group, F: 14 g/kg SAO+ANA-12 group, G: ANA-12 group.
图13为动物实验二的各组大鼠海马组织中BDNF、p-TrkB、p-AKT和p-CREB蛋白表达量比较结果,注:*p<0.05表示差异显著。FIG. 13 is a comparison of the expression levels of BDNF, p-TrkB, p-AKT and p-CREB proteins in the hippocampal tissue of each group of rats in the animal experiment 2. Note: *p<0.05 indicates significant difference.
具体实施方式DETAILED DESCRIPTION
下面结合具体实施例对本发明作进一步详细的说明,但本发明的实施方式不限于此。下列实施例中涉及的物料均可从商业渠道获得。The present invention is further described in detail below in conjunction with specific examples, but the embodiments of the present invention are not limited thereto. The materials involved in the following examples can all be obtained from commercial channels.
实施例1Example 1
本实施例的抗抑郁的中药膏,以质量份计其原料组成为:熟附子60g、干姜60g、炙甘草90g、桂枝90g、白芍90g、牡蛎300g、制山萸肉90g、乌梅45g、茯神150g、酸枣仁150g、大枣90g、淮山药150g、巴戟天60g、麦冬90g、砂仁30g、沉香粉末30g、肉桂30g、黄精120g、龟甲胶15g、阿胶15g、鹿角胶15g。The antidepressant Chinese medicine ointment of the present embodiment is composed of the following raw materials in parts by mass: 60g of cooked aconite, 60g of dried ginger, 90g of roasted licorice, 90g of cinnamon twig, 90g of white peony root, 300g of oyster, 90g of processed cornus fruit, 45g of ebony, 150g of poria, 150g of spiny jujube seed, 90g of jujube, 150g of Chinese yam, 60g of Morinda officinalis, 90g of Ophiopogon japonicus, 30g of Amomum villosum, 30g of agarwood powder, 30g of cinnamon, 120g of polygonatum, 15g of tortoise shell glue, 15g of donkey-hide glue, and 15g of deer antler glue.
其制备方法包括如下步骤:The preparation method thereof comprises the following steps:
(1)将熟附子、干姜、炙甘草、白芍、牡蛎、制山萸肉、乌梅、茯神、酸枣仁、大枣、淮山药、巴戟天、麦冬、黄精装入纱质大药袋,放入药罐中,添水没过药面浸泡20分钟,武火烧开后,文火熬制30分钟;(1) Put cooked aconite root, dried ginger, roasted licorice root, white peony root, oyster, processed cornus fruit, black plum, poria, spiny jujube seed, jujube, Chinese yam, Morinda officinalis, Ophiopogon japonicus, and polygonatum into a large gauze medicine bag, put it into a medicine pot, add water to cover the medicine surface and soak for 20 minutes, bring to a boil over high heat, and then simmer over low heat for 30 minutes;
(2)再将桂枝、砂仁、肉桂装入纱质小药袋,放入上述药罐中,继续熬制20分钟,然后将药液滤出,备用;(2) Place cinnamon twig, amomum villosum and cinnamon bark into a small gauze medicine bag, place it into the above medicine pot, and continue to boil for 20 minutes, then filter out the medicine liquid and set aside;
(3)向上述药罐中加入相同水量,对药渣同法熬制后,将药液滤出,与第一次滤出的药液合并,得到合并药液,备用;(3) adding the same amount of water to the above medicine tank, boiling the medicine residue in the same way, filtering out the medicine liquid, and combining it with the medicine liquid filtered out for the first time to obtain a combined medicine liquid for standby use;
(4)将龟甲胶、阿胶、鹿角胶放入容器中,加入约45mL 80℃左右的温水加热烊化后,与上述合并药液混合均匀,分为三等分,早、中、晚分别服用一份,临用时将沉香粉末分为三等分,分别加入一份沉香粉末冲服,3个月为一个疗程。(4) Place tortoise shell glue, donkey-hide gelatin and deer antler glue in a container, add about 45 mL of warm water at about 80°C, heat to melt, mix evenly with the above combined liquid medicine, divide into three equal parts, take one portion in the morning, noon and evening respectively. When taking, divide agarwood powder into three equal parts, add one portion of agarwood powder to each portion and take with water. A course of treatment is 3 months.
对制备的中药膏的成分进行了表征,表征方法及结果如下:The components of the prepared traditional Chinese medicine ointment were characterized, and the characterization method and results are as follows:
(1)色谱条件:色谱柱为ACE Excel 3Super C18柱(2.1×100mm×1.8μm),流动相:0.1%甲酸水(A)-乙腈(B),梯度洗脱,洗脱程序为:0-1min 10%B,1-2.5min 10%-25%B,2.5-8.5min 25%~95%B,8.5-12min 95%-95%B,12-12.01min 95%-100%B。流速为0.3mL/min;柱温30℃;进样量为2μL。(1) Chromatographic conditions: The chromatographic column was an ACE Excel 3Super C18 column (2.1×100 mm×1.8 μm), the mobile phase was 0.1% formic acid water (A)-acetonitrile (B), gradient elution, and the elution program was: 0-1 min 10% B, 10%-25% B, 2.5-8.5 min 25%-95% B, 8.5-12 min 95%-95% B, 12-12.01 min 95%-100% B. The flow rate was 0.3 mL/min; the column temperature was 30°C; and the injection volume was 2 μL.
(2)质谱条件:ESI离子源,采集数据(正负两种离子M模式),数据全扫描采集模式为IDA-production。一级质量扫描范围m/z 50-1000,IDA模式下质量扫描范围为m/z 50-1000;毛细管电压:5.5kV,锥孔电压:80V,离子源温度:600℃,脱溶剂气温度:600℃,雾化气(N2)流速:55L·h-1,脱溶剂气(N2)流速:55L·h-1,数据采集与处理采用Analyst TF 1.6软件。(2) Mass spectrometry conditions: ESI ion source, data acquisition (positive and negative ion M mode), data full scan acquisition mode is IDA-production. Primary mass scan range is m/z 50-1000, mass scan range is m/z 50-1000 in IDA mode; capillary voltage: 5.5 kV, cone voltage: 80 V, ion source temperature: 600 °C, desolvation temperature: 600 °C, nebulizer gas (N 2 ) flow rate: 55 L·h -1 , desolvation gas (N 2 ) flow rate: 55 L·h -1 , data acquisition and processing are performed using Analyst TF 1.6 software.
(3)在上述液-质联用色谱条件下,对实施例1制备的中药膏样品(浓度5.18mg/mL)进样分析,经化学式反向推导,共鉴定出15个色谱峰,主要是黄酮和萜类化合物,样品正负离子流图如图1-2所示;部分活性成分的二级离子流图如图3-6所示;基峰离子色谱相关质谱信息见表1。(3) Under the above-mentioned LC-MS/MS conditions, the Chinese medicine ointment sample (concentration 5.18 mg/mL) prepared in Example 1 was injected and analyzed. After reverse deduction of the chemical formula, a total of 15 chromatographic peaks were identified, which were mainly flavonoids and terpenoid compounds. The positive and negative ion chromatograms of the samples are shown in Figures 1-2; the secondary ion chromatograms of some active ingredients are shown in Figures 3-6; the mass spectrum information related to the base peak ion chromatogram is shown in Table 1.
表1中药膏样品中化学成分质谱信息Table 1 Mass spectrometry information of chemical components in traditional Chinese medicine ointment samples
实施例2Example 2
本实施例的抗抑郁的中药膏,以质量份计其原料组成为:The antidepressant Chinese medicine ointment of this embodiment has the following raw materials in parts by mass:
熟附子60g、干姜60g、炙甘草90g、桂枝90g、白芍90g、牡蛎300g、制山萸肉90g、乌梅45g、茯神150g、酸枣仁150g、大枣90g、淮山药150g、巴戟天60g、麦冬90g、砂仁30g、沉香30g、肉桂30g、黄精120g、龟甲胶15g、阿胶15g、鹿角胶15g。60g of cooked aconite, 60g of dried ginger, 90g of roasted licorice, 90g of cinnamon twig, 90g of white peony root, 300g of oyster, 90g of processed cornus fruit, 45g of black plum, 150g of poria, 150g of spiny jujube kernel, 90g of jujube, 150g of Chinese yam, 60g of Morinda officinalis, 90g of Ophiopogon japonicus, 30g of Amomum villosum, 30g of agarwood, 30g of cinnamon, 120g of Polygonatum sibiricum, 15g of tortoise shell glue, 15g of donkey-hide glue, and 15g of deer antler glue.
其制备方法包括如下步骤:The preparation method thereof comprises the following steps:
(1)取熟附子、干姜、炙甘草、桂枝、白芍、牡蛎、制山萸肉、乌梅、茯神、酸枣仁、大枣、淮山药、巴戟天、麦冬、砂仁、沉香、肉桂、黄精饮片,加入10倍量水浸泡1h后,煎煮1.5h,收集水煎液,药渣再用10倍量水煎煮1.5h,收集水煎液,合并2次水煎液,得到合并水煎液;(1) Take the pieces of cooked aconite, dried ginger, roasted licorice, cinnamon twig, white peony root, oyster, processed cornus fruit, black plum, poria, spiny jujube seed, jujube, Chinese yam, Morinda officinalis, Ophiopogon japonicus, Amomum villosum, agarwood, cinnamon bark, and polygonatum, add 10 times the amount of water to soak for 1 hour, decoct for 1.5 hours, collect the decoction, decoct the residue with 10 times the amount of water for 1.5 hours, collect the decoction, combine the two decoctions to obtain a combined decoction;
(2)将龟甲胶、阿胶、鹿角胶用温水烊化后兑入步骤(1)得到的合并水煎液中,过滤,将得到的药液减压浓缩,得到浸膏212.8g。(2) Melt tortoise shell glue, donkey-hide glue and deer antler glue with warm water and add them to the combined water decoction obtained in step (1), filter and concentrate the obtained medicinal solution under reduced pressure to obtain 212.8 g of extract.
实施例3Example 3
本实施例的抗抑郁的中药膏,以质量份计其原料组成为:The antidepressant Chinese medicine ointment of this embodiment has the following raw materials in parts by mass:
熟附子60g、干姜60g、炙甘草90g、桂枝90g、白芍90g、牡蛎300g、制山萸肉90g、乌梅45g、茯神150g、酸枣仁150g、大枣90g、淮山药150g、巴戟天60g、麦冬90g、砂仁30g、沉香30g、肉桂30g、黄精120g、龟甲胶15g、阿胶15g、鹿角胶15g。60g of cooked aconite, 60g of dried ginger, 90g of roasted licorice, 90g of cinnamon twig, 90g of white peony root, 300g of oyster, 90g of processed cornus fruit, 45g of black plum, 150g of poria, 150g of spiny jujube kernel, 90g of jujube, 150g of Chinese yam, 60g of Morinda officinalis, 90g of Ophiopogon japonicus, 30g of Amomum villosum, 30g of agarwood, 30g of cinnamon, 120g of Polygonatum sibiricum, 15g of tortoise shell glue, 15g of donkey-hide glue, and 15g of deer antler glue.
其制备方法包括如下步骤:The preparation method thereof comprises the following steps:
(1)将除了沉香、龟甲胶、阿胶、鹿角胶之外的原料药材加入10倍量的水中,浸泡1小时,然后煎煮2次,每次煎煮时间为煮沸后继续煎煮1.5小时,合并2次煎煮得到的煎煮液,过80目筛滤过,得到煎煮药液;(1) adding the raw medicinal materials except agarwood, tortoise shell glue, donkey-hide gelatin, and deer antler glue to 10 times the amount of water, soaking for 1 hour, and then decocting twice, each decoction time is continued for 1.5 hours after boiling, combining the decoctions obtained from the two decoctions, filtering through an 80-mesh sieve, and obtaining a decoction liquid;
(2)将步骤(1)得到的煎煮药液在80℃下加热浓缩至相对密度为1.30(室温)的第一清膏;(2) heating the decoction obtained in step (1) at 80° C. and concentrating it to a first clear paste having a relative density of 1.30 (at room temperature);
(3)将龟甲胶、阿胶和鹿角胶混合,加入约45mL的水,然后升温至70℃进行加热烊化,烊化后再加入步骤(2)得到的第一清膏中,并搅拌均匀,得到第二清膏;(3) Mix tortoise shell glue, donkey hide glue and deer antler glue, add about 45 mL of water, and then heat to 70° C. to melt, and then add to the first clear paste obtained in step (2) after melting, and stir evenly to obtain a second clear paste;
(4)将沉香过120目筛得到沉香粉末,将步骤(3)得到的第二清膏加热升温至60℃后,再加入沉香粉末,搅拌混合均匀,得到混合药物;(4) Passing agarwood through a 120-mesh sieve to obtain agarwood powder, heating the second clear paste obtained in step (3) to 60° C., adding the agarwood powder, stirring and mixing evenly to obtain a mixed medicine;
(5)向步骤(4)得到的混合药物中按照1:1的质量比加入中蜜,然后加热至60℃,搅拌均匀,得到相对密度为1.44(室温)的成品膏;(5) adding medium honey to the mixed drug obtained in step (4) at a mass ratio of 1:1, then heating to 60° C. and stirring evenly to obtain a finished paste with a relative density of 1.44 (room temperature);
(6)将步骤(5)所得成品膏放凉后进行罐装,灭菌,即得。将得到的煎膏剂以100mL/瓶密封保存,晨起空腹时服用,一次服用20mL,3个月为一个疗程。(6) Cool the finished paste obtained in step (5) and then can it for sterilization. The decoction is sealed and stored in 100 mL/bottle, and taken in the morning on an empty stomach, 20 mL at a time, and a course of treatment is 3 months.
实施例4Example 4
本实施例的抗抑郁的中药膏,以质量份计其原料组成为:The antidepressant Chinese medicine ointment of this embodiment has the following raw materials in parts by mass:
熟附子55g、干姜55g、炙甘草85g、桂枝85g、白芍85g、牡蛎290g、制山萸肉85g、乌梅40g、茯神145g、酸枣仁145g、大枣85g、淮山药145g、巴戟天55g、麦冬85g、砂仁25g、沉香25g、肉桂25g、黄精115g、龟甲胶10g、阿胶10g、鹿角胶10g。Cooked aconite 55g, dried ginger 55g, roasted licorice root 85g, cinnamon twig 85g, white peony root 85g, oyster 290g, processed cornus fruit 85g, black plum 40g, poria 145g, spiny jujube seed 145g, jujube 85g, Chinese yam 145g, Morinda officinalis 55g, Ophiopogon japonicus 85g, Amomum villosum 25g, agarwood 25g, cinnamon 25g, Polygonatum 115g, tortoise shell glue 10g, donkey-hide glue 10g, deer antler glue 10g.
其制备方法与实施例3的相同。The preparation method is the same as that of Example 3.
实施例5Example 5
本实施例的抗抑郁的中药膏,以质量份计其原料组成为:The antidepressant Chinese medicine ointment of this embodiment has the following raw materials in parts by mass:
熟附子65g、干姜65g、炙甘草95g、桂枝95g、白芍95g、牡蛎310g、制山萸肉95g、乌梅55g、茯神155g、酸枣仁155g、大枣95g、淮山药155g、巴戟天65g、麦冬95g、砂仁35g、沉香35g、肉桂35g、黄精125g、龟甲胶20g、阿胶20g、鹿角胶20g。Cooked aconite 65g, dried ginger 65g, roasted licorice root 95g, cinnamon twig 95g, white peony root 95g, oyster 310g, processed cornus fruit 95g, black plum 55g, poria 155g, spiny jujube seed 155g, jujube 95g, Chinese yam 155g, Morinda officinalis 65g, Ophiopogon japonicus 95g, Amomum villosum 35g, agarwood 35g, cinnamon bark 35g, Polygonatum 125g, tortoise shell glue 20g, donkey-hide glue 20g, deer antler glue 20g.
其制备方法与实施例3的相同。The preparation method is the same as that of Example 3.
为了探究本发明的抗抑郁的中药组合物对抑郁症的治疗效果,采用实施例2、3制备的抗抑郁的中药膏进行以下动物实验。In order to explore the therapeutic effect of the antidepressant Chinese medicine composition of the present invention on depression, the antidepressant Chinese medicine ointment prepared in Examples 2 and 3 was used to conduct the following animal experiments.
动物实验一Animal Experiment 1
1.实验材料1. Experimental Materials
1.1实验动物:SPF级ICR小鼠60只,3-4周龄,体重18-22g,浙江维通利华实验动物技术有限公司提供,动物生产许可证号SCXK(浙)2019-0001,动物使用许可证号:SYXK(川)2018-100。1.1 Experimental animals: 60 SPF-grade ICR mice, 3-4 weeks old, weighing 18-22 g, provided by Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd., Animal Production License No. SCXK(Zhejiang)2019-0001, Animal Use License No.: SYXK(Sichuan)2018-100.
1.2实验仪器:化学发光成像系统(ChemiScope6100上海勤翔科学仪器有限公司);光谱仪(BioTekμQuant美国伯腾);转印槽及组件(Bio-Rad Laboratories Mini Trans-Blot Cell);高速冷冻离心机(SCILOGEX D3024R,美国赛洛捷克);高速低温组织研磨仪(servicebio KZ-III-F);转轮式切片机(徕卡-2016,德国徕卡);数字切片扫描仪(Pannoramic 250,3DHISTECH)。1.2 Experimental instruments: chemiluminescence imaging system (ChemiScope6100, Shanghai Qinxiang Scientific Instrument Co., Ltd.); spectrometer (BioTekμQuant, USA); transfer tank and components (Bio-Rad Laboratories Mini Trans-Blot Cell); high-speed refrigerated centrifuge (SCILOGEX D3024R, USA); high-speed cryogenic tissue grinder (servicebio KZ-III-F); rotary microtome (Leica-2016, Leica, Germany); digital slice scanner (Pannoramic 250, 3DHISTECH).
1.3实验药物:1.3 Experimental drugs:
实施例2制备的抗抑郁的中药膏。The antidepressant Chinese medicinal ointment prepared in Example 2.
盐酸丙米嗪,批号AF22031806,规格20mg/瓶,由成都埃法生物科技有限公司提供。Imipramine hydrochloride, batch number AF22031806, specification 20 mg/bottle, provided by Chengdu Aifa Biotechnology Co., Ltd.
1.4试剂:皮质酮(批号AFBH0905),由成都埃法生物科技有限公司提供;甲苯胺蓝染液(批号CR2102004),由武汉塞维尔生物科技有限公司提供;BDNF、Trkb、CREB、p-Akt、Akt抗体,由英国abcam-艾博抗(上海)贸易有限公司提供;GAPDH(批号Mab5465),由杭州联科生物技术有限公司提供;BCA蛋白浓度测定试剂盒(批号AR0146),由武汉博士德生物工程有限公司提供。1.4 Reagents: Corticosterone (Batch No. AFBH0905), provided by Chengdu Aifa Biotechnology Co., Ltd.; Toluidine blue dye (Batch No. CR2102004), provided by Wuhan Sewell Biotechnology Co., Ltd.; BDNF, Trkb, CREB, p-Akt, Akt antibodies, provided by abcam-Abcam (Shanghai) Trading Co., Ltd., UK; GAPDH (Batch No. Mab5465), provided by Hangzhou Lianke Biotechnology Co., Ltd.; BCA protein concentration determination kit (Batch No. AR0146), provided by Wuhan Boster Bioengineering Co., Ltd.
2.实验方法2. Experimental Methods
2.1动物分组:SPF级别的ICR小鼠60只,雄性,体重18-22g,适应性饲养5~7天后,采用随机数字表法将实验小鼠分成6组,每组10只;分为正常对照组、模型组、低剂量中药膏组、中剂量中药膏组、高剂量中药膏组和阳性药组。2.1 Animal grouping: 60 SPF-level ICR mice, male, weighing 18-22 g, were adaptively fed for 5-7 days and then divided into 6 groups using a random number table, with 10 mice in each group; they were divided into a normal control group, a model group, a low-dose Chinese medicine ointment group, a medium-dose Chinese medicine ointment group, a high-dose Chinese medicine ointment group, and a positive drug group.
2.2动物模型建立及给药:除正常对照组不做其他处理,保持正常饮水进食外,其余各组小鼠皮下注射皮质酮0.01g/kg造模,一天注射一次,共注射28天,造模与给药同时进行。2.2 Establishment of animal model and drug administration: Except for the normal control group which did not receive other treatment and maintained normal drinking water and food intake, the mice in other groups were subcutaneously injected with 0.01 g/kg of corticosterone to establish the model, once a day for a total of 28 days. Model establishment and drug administration were carried out simultaneously.
正常对照组与模型组灌胃等量生理盐水,阳性药组与各剂量中药膏组按体重标准灌胃给药,具体给药剂量为:The normal control group and the model group were gavaged with an equal amount of normal saline, and the positive drug group and the Chinese medicine ointment groups of various doses were gavaged with drugs according to the body weight standard. The specific dosages were:
低剂量中药膏组:实施例2制备的抗抑郁的中药膏,给药剂量4.10g/kg;Low-dose Chinese medicine ointment group: the antidepressant Chinese medicine ointment prepared in Example 2, with a dosage of 4.10 g/kg;
中剂量中药膏组:实施例2制备的抗抑郁的中药膏,给药剂量12.3g/kg;Medium-dose Chinese medicine ointment group: the antidepressant Chinese medicine ointment prepared in Example 2, with a dosage of 12.3 g/kg;
高剂量中药膏组:实施例2制备的抗抑郁的中药膏,给药剂量20.5g/kg;High-dose Chinese medicine ointment group: the antidepressant Chinese medicine ointment prepared in Example 2, with a dosage of 20.5 g/kg;
阳性药组:丙米嗪,给药剂量0.02g/kg。Positive drug group: imipramine, the dosage was 0.02 g/kg.
给药体积10mL·kg-1,每日1次,记录饲料消耗量、体重变化、小鼠状态等,连续灌胃给药28天。The administration volume was 10 mL·kg -1 , once a day, and the feed consumption, body weight changes, mouse status, etc. were recorded. The administration was continued by intragastric administration for 28 days.
2.3体质量检测:各组小鼠在适应期、造模及给药后0-4周期间,在相同饲养环境条件下,记录各组受试小鼠体质量的变化情况。2.3 Body weight detection: During the adaptation period, modeling and 0-4 weeks after administration, the body weight changes of each group of mice were recorded under the same breeding environment conditions.
2.4蔗糖偏好实验(SPT):实验前,先对小鼠进行适应性训练3天,即在笼内放置两个瓶子,一个瓶子装有1wt%蔗糖水,另一个瓶子装有常规饮用水,两个瓶子的位置每天都会交换(从左到右,从右到左)。适应性训练结束后禁食、禁水24h。鼠笼内准备1瓶常规饮用水与1瓶1wt%的蔗糖水。待1h后结束实验,记录小鼠饮用水与蔗糖水摄取量。结果判定:蔗糖偏好值(%)=[蔗糖水摄取量/(蔗糖水摄取量+纯水摄取量)]×100%。2.4 Sucrose preference test (SPT): Before the experiment, mice were subjected to adaptive training for 3 days, that is, two bottles were placed in the cage, one bottle contained 1wt% sucrose water, and the other bottle contained regular drinking water. The positions of the two bottles were swapped every day (from left to right, from right to left). After the adaptive training, the mice were fasted and deprived of water for 24 hours. Prepare 1 bottle of regular drinking water and 1 bottle of 1wt% sucrose water in the mouse cage. The experiment was terminated after 1 hour, and the mice's intake of drinking water and sucrose water was recorded. Result determination: Sucrose preference value (%) = [sucrose water intake/(sucrose water intake + pure water intake)] × 100%.
2.5强迫游泳实验(FST):在测试前1天对小鼠进行预实验,将小鼠置于透明圆筒(高25cm,直径15cm,水温25±2℃,水深10cm)中,预测时长为12min,随后取出,擦干放入笼中。测试当天,将小鼠再次放入相同的环境进行测试,测试时长6min。结果判定:对每一只小鼠测试的后4min进行记录,记录小鼠在水中保持“不动状态”的时间。2.5 Forced swimming test (FST): The mice were pre-tested 1 day before the test. The mice were placed in a transparent cylinder (25 cm high, 15 cm in diameter, 25 ± 2 °C in water temperature, 10 cm in water depth) for a predicted duration of 12 min. They were then taken out, dried and placed in a cage. On the day of the test, the mice were placed in the same environment again for a test duration of 6 min. Result determination: The last 4 min of the test for each mouse was recorded, and the time the mouse remained in the "immobile state" in the water was recorded.
2.6新奇抑制摄食实验(NSF):测试前禁食24h,测试时,将普通小鼠食物颗粒放在鼠笼内中央的白纸平台上。每只鼠都被放在盒子的一角,允许探索长达5min。计时结束还没有进食,按5min计算,记录小鼠首次进食食物颗粒的时间为潜伏期。小鼠在嗅食物或者搬运食物都不计入潜伏期,只有当小鼠开始啃食食物才开始记录。2.6 Novelty Suppression of Food Intake (NSF): The mice were fasted for 24 hours before the test. During the test, ordinary mouse food pellets were placed on a white paper platform in the center of the cage. Each mouse was placed in a corner of the box and allowed to explore for up to 5 minutes. If the mouse had not eaten at the end of the timer, it was calculated as 5 minutes, and the time when the mouse first ate the food pellets was recorded as the latency. The latency period was not counted when the mouse smelled or carried the food. The latency period was only recorded when the mouse started to gnaw on the food.
2.7脑组织尼氏染色分析:行为学检测结束后,将小鼠用4%水合氯醛麻醉,在冰上迅速取出小鼠脑组织放入4%多聚甲醛固定15min,经脱水、包埋、切片制作石蜡切片,放入尼氏染液中,待尼氏体清晰后终止反应,显微镜下观察并拍摄尼氏体的变化。2.7 Nissl staining analysis of brain tissue: After the behavioral test, the mice were anesthetized with 4% chloral hydrate, and the brain tissue of the mice was quickly removed on ice and fixed in 4% paraformaldehyde for 15 minutes. The paraffin sections were made after dehydration, embedding, and slicing, and then placed in Nissl staining solution. The reaction was terminated when the Nissl bodies became clear, and the changes of Nissl bodies were observed and photographed under a microscope.
2.8Western blot法检测脑组织蛋白表达:分离小鼠海马区域脑组织,放入2mL研磨管中,然后向每管加入3mm钢珠及RIPA裂解液(按照质量比,样本:裂解液=1:10),置于高速低温组织研磨仪内(温度-20℃,研磨4次,每次60s);取出放4℃冰箱30min进行裂解,30min后取出放入离心机(4℃、12000rpm离心10min);离心完后取上清液,用BCA蛋白浓度测定试剂盒测定蛋白浓度。取蛋白质样品30μg,在稳定电压100V下电泳,转印蛋白至PVDF膜,缓冲液(注:缓冲液为用TBST Buffer稀释的5%脱脂牛奶,由武汉谷歌生物科技有限公司提供)室温摇床封闭2h,加一抗BDNF(1:1000)、Trkb(1:1000)、p-Akt(1:1000)、Akt(1:2000)、CREB(1:1000)。Tris-HCl缓冲盐溶液洗膜10min×3次,加入辣根过氧化物酶标记的二抗(1:10000)(注:二抗为HRP标记山羊抗兔),37℃反应1h,洗膜10min×3次,曝光后显影、定影,采用ChemiScope6100测定条带吸光度,选择GAPDH为内参照。2.8 Western blot method to detect brain tissue protein expression: The brain tissue of the hippocampus region of mice was separated and placed in a 2 mL grinding tube, and then 3 mm steel beads and RIPA lysis solution (by mass ratio, sample: lysis solution = 1:10) were added to each tube, and placed in a high-speed low-temperature tissue grinder (temperature -20°C, grind 4 times, each time for 60 s); taken out and placed in a 4°C refrigerator for 30 minutes for lysis, taken out after 30 minutes and placed in a centrifuge (4°C, 12000 rpm centrifugation for 10 minutes); after centrifugation, the supernatant was taken and the protein concentration was determined using a BCA protein concentration assay kit. 30 μg of protein sample was taken, electrophoresed at a stable voltage of 100 V, and the protein was transferred to PVDF membrane, and the buffer (Note: the buffer is 5% skim milk diluted with TBST Buffer, provided by Wuhan Google Biotechnology Co., Ltd.) was blocked on a shaker at room temperature for 2 hours, and primary antibodies BDNF (1:1000), Trkb (1:1000), p-Akt (1:1000), Akt (1:2000), CREB (1:1000) were added. The membrane was washed with Tris-HCl buffer solution for 10 min × 3 times, and horseradish peroxidase-labeled secondary antibody (1:10000) (Note: the secondary antibody is HRP-labeled goat anti-rabbit) was added, reacted at 37°C for 1 hour, and the membrane was washed for 10 min × 3 times. After exposure, it was developed and fixed, and the band absorbance was measured using ChemiScope6100, and GAPDH was selected as the internal reference.
2.9统计学处理:统计学分析用Graph Pad Prism 9.0.0(86)进行,以均数±标准差表示,组间差异采用SPSS统计软件进行单因素方差分析(ANOVA),单因素方差分析在组间比较,以P<0.05为差异具有显著性。2.9 Statistical analysis: Statistical analysis was performed using Graph Pad Prism 9.0.0 (86) and presented as mean ± standard deviation. The differences among the groups were analyzed by one-way analysis of variance (ANOVA) using SPSS statistical software. The differences among the groups were considered significant when P < 0.05.
3.实验结果3. Experimental results
3.1对皮质酮诱导抑郁症模型小鼠体质量的影响3.1 Effects on body weight of mice with corticosterone-induced depression model
各组小鼠体质量测定结果如图7所示,从图7可以看出,给药后,与正常对照组比较,模型组小鼠体质量在第28天显著降低(P<0.05);与模型组比较,阳性药组、各剂量中药膏组小鼠体质量显著增加(P<0.05)。由上述结果可知,本发明的中药组合物能增加抑郁症模型小鼠的体质量,改善抑郁症小鼠生长迟缓状态。The results of the body weight measurement of mice in each group are shown in Figure 7. It can be seen from Figure 7 that after administration, the body weight of mice in the model group was significantly reduced on the 28th day compared with the normal control group (P < 0.05); compared with the model group, the body weight of mice in the positive drug group and each dose of Chinese medicine ointment group was significantly increased (P < 0.05). From the above results, it can be seen that the Chinese medicine composition of the present invention can increase the body weight of depression model mice and improve the growth retardation of depression mice.
3.2对皮质酮诱导抑郁症模型小鼠蔗糖偏好的影响3.2 Effects on sucrose preference in mice with corticosterone-induced depression
各组小鼠蔗糖偏好测定结果如表2所示:The results of sucrose preference test of mice in each group are shown in Table 2:
表2各组小鼠蔗糖偏好测定结果Table 2 Results of sucrose preference test for mice in each group
注:表中,#表示与正常对照组相比,P<0.05;*表示与模型组相比,P<0.05。Note: In the table, # indicates P<0.05 compared with the normal control group; * indicates P<0.05 compared with the model group.
从表2可以看出,模型组小鼠的蔗糖偏好值明显低于正常对照组,差异具有显著性(P<0.05),说明抑郁症小鼠模型构建成功。低、中、高剂量中药膏组小鼠的蔗糖偏好值均显著高于模型组,差异具有显著性(P<0.05或P<0.01),且低、中、高剂量中药膏组的效果均优于阳性药组,其中低剂量中药膏组的效果最好。As can be seen from Table 2, the sucrose preference value of the model group mice was significantly lower than that of the normal control group, and the difference was significant (P<0.05), indicating that the depression mouse model was successfully established. The sucrose preference values of the mice in the low, medium and high doses of Chinese medicine ointment groups were significantly higher than those in the model group, and the difference was significant (P<0.05 or P<0.01), and the effects of the low, medium and high doses of Chinese medicine ointment groups were better than those of the positive drug group, among which the low dose of Chinese medicine ointment group had the best effect.
3.3对皮质酮诱导抑郁症模型小鼠强迫游泳的影响3.3 Effects of forced swimming on corticosterone-induced depression model mice
各组小鼠游泳不动时间测定结果如表3所示:The results of the swimming immobility time measurement of mice in each group are shown in Table 3:
表3各组小鼠游泳不动时间测定结果Table 3 Results of the swimming immobility time of mice in each group
注:表中,#表示与正常对照组相比,P<0.05;*表示与模型组相比,P<0.05。Note: In the table, # indicates P<0.05 compared with the normal control group; * indicates P<0.05 compared with the model group.
从表3可以看出,与正常对照组小鼠对比,模型组小鼠在水中静止不动时间明显升高,差异具有显著性(P<0.05),说明抑郁症小鼠模型构建成功。阳性药组和低、中、高剂量中药膏组在水中静止不动时间均显著低于模型组,差异具有显著性(P<0.05),其中,中、高剂量中药膏组的效果均优于阳性药组,高剂量中药膏组的效果最好。As can be seen from Table 3, compared with the normal control group mice, the immobility time of the model group mice in the water was significantly increased, and the difference was significant (P<0.05), indicating that the depression mouse model was successfully established. The immobility time of the positive drug group and the low, medium and high doses of Chinese medicine ointment groups in the water was significantly lower than that of the model group, and the difference was significant (P<0.05). Among them, the effects of the medium and high doses of Chinese medicine ointment groups were better than those of the positive drug group, and the high dose of Chinese medicine ointment group had the best effect.
3.4对皮质酮诱导抑郁症小鼠模型新奇抑制摄食实验的影响3.4 Effects of novelty suppression of food intake in the corticosterone-induced depression mouse model
各组小鼠进食潜伏期测定结果如表4所示:The results of the feeding latency test of each group of mice are shown in Table 4:
表4各组小鼠进食潜伏期测定结果Table 4 Results of feeding latency test of mice in each group
注:表中,#表示与正常对照组相比,P<0.05;*表示与模型组相比,P<0.05。Note: In the table, # indicates P<0.05 compared with the normal control group; * indicates P<0.05 compared with the model group.
从表4可以看出,与正常对照组比较,模型组小鼠在第28天进食潜伏期显著升高(P<0.05);与模型组比较,低、中、高剂量中药膏组和阳性药组小鼠进食潜伏期显著降低(P<0.05)。由上述结果可知,本发明的中药组合物能降低抑郁症小鼠进食潜伏期,改善抑郁症小鼠进食状态。As can be seen from Table 4, compared with the normal control group, the feeding latency of the model group mice on the 28th day was significantly increased (P < 0.05); compared with the model group, the feeding latency of the mice in the low, medium and high doses of Chinese medicine ointment groups and the positive drug group was significantly reduced (P < 0.05). From the above results, it can be seen that the Chinese medicine composition of the present invention can reduce the feeding latency of depression mice and improve the feeding state of depression mice.
3.5脑组织尼氏染色结果3.5 Nissl staining results of brain tissue
各组小鼠海马神经元的测定结果如图8所示。从图8可以看出,与正常对照组比较,模型组的神经元形态异常,染色较浅,部分神经元发生萎缩变形,基质更为疏松,尼氏小体明显减少。与模型组比较,低、中、高剂量中药膏组及阳性药组的神经元数量多而密集,形态饱满,说明本发明的中药组合物显示出对抑郁症模型小鼠神经可塑性的保护作用。The results of the determination of hippocampal neurons in each group of mice are shown in Figure 8. As can be seen from Figure 8, compared with the normal control group, the neurons in the model group were abnormal in morphology, with lighter staining, some neurons were atrophied and deformed, the matrix was looser, and the Nissl bodies were significantly reduced. Compared with the model group, the number of neurons in the low, medium, and high doses of Chinese medicine ointment groups and the positive drug group was large and dense, and the morphology was full, indicating that the Chinese medicine composition of the present invention showed a protective effect on the neuroplasticity of depression model mice.
3.6 Western blot蛋白表达分析结果3.6 Western blot protein expression analysis results
各组小鼠海马组织中Trkb、CREB、BDNF和p-Akt蛋白表达条带图如图9所示,小鼠海马组织相关蛋白表达的测定结果如表5所示。The expression band diagrams of Trkb, CREB, BDNF and p-Akt proteins in the hippocampus tissue of mice in each group are shown in FIG9 . The results of the determination of the expression of related proteins in the hippocampus tissue of mice are shown in Table 5 .
表5小鼠海马组织相关蛋白表达的测定结果Table 5 Determination results of related protein expression in mouse hippocampus tissue
注:表中,#表示与正常对照组相比,P<0.05;*表示与模型组相比,P<0.05,**表示与模型组相比,P<0.01。Note: In the table, # indicates that compared with the normal control group, P <0.05; * indicates that compared with the model group, P <0.05; ** indicates that compared with the model group, P < 0.01.
从图9和表5可以看出,与正常对照组比较,模型组小鼠BDNF、Trkb、CREB和p-Akt/Akt表达水平显著降低(P<0.05);与模型组比较,低、中、高剂量中药膏组BDNF、Trkb、CREB和p-Akt表达水平显著升高(P<0.05)。As can be seen from Figure 9 and Table 5, compared with the normal control group, the expression levels of BDNF, Trkb, CREB and p-Akt/Akt in the model group were significantly decreased (P < 0.05); compared with the model group, the expression levels of BDNF, Trkb, CREB and p-Akt in the low, medium and high doses of Chinese medicine ointment groups were significantly increased (P < 0.05).
综上,本发明的中药组合物可能通过其含有的莫诺苷、马钱苷、芍药苷、姜辣素(即6-姜酚)、斯皮诺素等活性成分影响抑郁症模型小鼠的BDNF/Trkb信号通路及下游相关蛋白等来发挥抗抑郁症的作用,其机制可能与上调Trkb、p-Akt、BDNF以及CREB蛋白表达,改善海马神经元的可塑性有关。In summary, the Chinese medicine composition of the present invention may exert its anti-depressant effect by affecting the BDNF/Trkb signaling pathway and downstream related proteins in depression model mice through the active ingredients contained therein, such as morroniside, loganin, paeoniflorin, gingerol (i.e., 6-gingerol), and spinosin. Its mechanism may be related to upregulating the expression of Trkb, p-Akt, BDNF and CREB proteins and improving the plasticity of hippocampal neurons.
动物实验二Animal Experiment II
1.实验材料1. Experimental Materials
1.1实验动物:84只SD大鼠,雌雄各半,体重220±20g,由北京华阜康生物科技技术有限公司提供,动物生产许可证号:SCXK(京)2019-0008。动物使用许可证号:SYXK(川)2018-100,伦理审查批准号:SYLL(2023)-028。1.1 Experimental animals: 84 SD rats, half male and half female, weighing 220±20 g, provided by Beijing Huafukang Biotechnology Co., Ltd., Animal Production License No.: SCXK(Beijing)2019-0008. Animal Use License No.: SYXK(Sichuan)2018-100, Ethics Review Approval No.: SYLL(2023)-028.
1.2实验仪器与材料:主要实验仪器与材料如表6所示。1.2 Experimental instruments and materials: The main experimental instruments and materials are shown in Table 6.
表6实验仪器与材料Table 6 Experimental instruments and materials
1.3实验药物:1.3 Experimental drugs:
实施例3制备的抗抑郁的中药膏。The antidepressant Chinese medicinal ointment prepared in Example 3.
氟西汀,编号mrbk2101,规格100mg/瓶,由成都埃法生物科技有限公司提供。Fluoxetine, code number mrbk2101, specification 100 mg/bottle, provided by Chengdu Aifa Biotechnology Co., Ltd.
ANA-12(TrkB拮抗剂),编号AFBJ1075,由成都埃法生物科技有限公司提供。ANA-12 (TrkB antagonist), number AFBJ1075, was provided by Chengdu Aifa Biotechnology Co., Ltd.
2.实验方法2. Experimental Methods
2.1动物分组:84只SD大鼠雌雄各半,体重220±20g,适应性饲养5~7天后,采用随机数字表法将实验小鼠分成7组,每组12只;7组分别为正常对照组(简称对照组)、模型组(简称CUMS组)、中剂量中药膏组(简称8.4g/kg SAO组)、高剂量中药膏组(简称14g/kg SAO组)、氟西汀阳性药对照组(简称氟西汀组)、高剂量中药膏+ANA-12组(简称14g/kg SAO+ANA-12组)和ANA-12组。2.1 Animal grouping: 84 SD rats, half male and half female, weighing 220±20 g, were adaptively fed for 5-7 days and then divided into 7 groups using a random number table, with 12 rats in each group; the 7 groups were normal control group (referred to as control group), model group (referred to as CUMS group), medium-dose Chinese medicine ointment group (referred to as 8.4 g/kg SAO group), high-dose Chinese medicine ointment group (referred to as 14 g/kg SAO group), fluoxetine positive drug control group (referred to as fluoxetine group), high-dose Chinese medicine ointment + ANA-12 group (referred to as 14 g/kg SAO + ANA-12 group) and ANA-12 group.
2.2 CUMS大鼠抑郁模型建立及给药:2.2 Establishment of CUMS rat depression model and drug administration:
模拟人类在日常生活中所面临的各种慢性压力:(1)12小时的明暗颠倒;(2)断食12小时;(3)断水12h;(4)倾斜笼体45度,放置12h;(5)在40℃的热水中游泳5min;(6)潮湿垫料24h;(7)樟脑球刺激24小时。除正常对照组外,其余大鼠连续接受上述慢性不可预知性刺激35天,每种应激刺激源不连续且不规律。造模与给药同时进行。The rats were simulated with various chronic stresses that humans face in daily life: (1) 12 hours of light-dark reversal; (2) 12 hours of fasting; (3) 12 hours of water deprivation; (4) 12 hours of cage tilt at 45 degrees; (5) 5 minutes of swimming in 40°C hot water; (6) 24 hours of wet bedding; (7) 24 hours of mothball stimulation. Except for the normal control group, the remaining rats were subjected to the above chronic unpredictable stimulation for 35 consecutive days. Each stress stimulus was discontinuous and irregular. Modeling and drug administration were carried out at the same time.
对照组与模型组灌胃等量生理盐水,其余各组按体重标准灌胃给药,具体给药剂量为:The control group and the model group were gavaged with an equal amount of normal saline, and the other groups were gavaged with drugs according to body weight. The specific dosages were:
8.4g/kg SAO组:实施例3制备的抗抑郁的中药膏,给药剂量8.4g/kg/d;8.4 g/kg SAO group: the antidepressant Chinese medicine ointment prepared in Example 3, the dosage was 8.4 g/kg/d;
14g/kg SAO组:实施例3制备的抗抑郁的中药膏,给药剂量14g/kg/d;14 g/kg SAO group: the antidepressant Chinese medicine ointment prepared in Example 3, with a dosage of 14 g/kg/d;
氟西汀组:氟西汀,给药剂量0.02g/kg/d;Fluoxetine group: Fluoxetine, dosage 0.02 g/kg/d;
14g/kg SAO+ANA-12组:同时给予实施例3制备的抗抑郁的中药膏和ANA-12,其中,中药膏给药剂量14g/kg/d,ANA-12给药剂量0.0005g/kg;14g/kg SAO+ANA-12 group: The antidepressant Chinese medicine ointment prepared in Example 3 and ANA-12 were administered simultaneously, wherein the dosage of the Chinese medicine ointment was 14g/kg/d, and the dosage of ANA-12 was 0.0005g/kg;
ANA-12组:ANA-12,给药剂量0.0005g/kg。ANA-12 group: ANA-12, dosage 0.0005 g/kg.
给药体积10mL·kg-1,每日1次,连续灌胃给药35天。The administration volume was 10 mL·kg -1 , once a day, for 35 consecutive days.
2.3蔗糖偏好实验(SPT):实验前,先对大鼠进行适应性训练3天,即在笼内放置两个瓶子,一个瓶子装有1wt%蔗糖水,另一个瓶子装有常规饮用水,两个瓶子的位置每天都会交换(从左到右,从右到左)。适应性训练结束后禁食、禁水24h。鼠笼内准备1瓶常规饮用水与1瓶1wt%的蔗糖水。待1h后结束实验,记录小鼠饮用水与蔗糖水摄取量。结果判定:蔗糖偏好值(%)=[蔗糖水摄取量/(蔗糖水摄取量+纯水摄取量)]×100%。2.3 Sucrose preference test (SPT): Before the experiment, rats were subjected to adaptive training for 3 days, that is, two bottles were placed in the cage, one bottle contained 1wt% sucrose water, and the other bottle contained regular drinking water. The positions of the two bottles were swapped every day (from left to right, from right to left). After the adaptive training, the rats were fasted and deprived of water for 24 hours. Prepare 1 bottle of regular drinking water and 1 bottle of 1wt% sucrose water in the mouse cage. The experiment was terminated after 1 hour, and the mice's intake of drinking water and sucrose water was recorded. Result determination: Sucrose preference value (%) = [sucrose water intake/(sucrose water intake + pure water intake)] × 100%.
2.4强迫游泳实验(FST):在测试前1天对大鼠进行预实验:将大鼠置于透明圆筒(高25cm,直径25cm,水温25±2℃,水深10cm)中,预测时长为12min,随后取出,擦干放入笼中。测试当天,将大鼠再次放入相同的环境进行测试,测试时长6min。结果判定:对每一只大鼠测试的后4min进行记录,记录大鼠在水中保持“不动状态”的时间。2.4 Forced swimming test (FST): A pre-experiment was conducted on rats 1 day before the test: the rats were placed in a transparent cylinder (25 cm high, 25 cm in diameter, water temperature 25 ± 2 °C, water depth 10 cm) for a predicted duration of 12 min, then taken out, dried and placed in a cage. On the day of the test, the rats were placed in the same environment again for a test duration of 6 min. Result determination: The last 4 min of the test for each rat was recorded, and the time the rat remained in the "immobile state" in the water was recorded.
2.5新奇抑制摄食实验(NSF):NSF旨在评估慢性抗抑郁药物治疗的抗焦虑和/或抗抑郁效果。测试仪由一个50×50×20cm的塑料盒组成。在测试时,禁食禁水48h后,将一粒称重的普通大鼠食物颗粒放在塑料盒中央的白纸平台上。每只鼠都被放在盒子的一角,大鼠适应1分钟后,允许探索长达5分钟。当老鼠咀嚼了一部分食物时,试验结束。以笼子中的食物消耗量作为5分钟内食物的消耗量。计时结束还没有进食,按5min计算,记录大鼠首次进食食物颗粒的时间为潜伏期。2.5 Novelty Suppressed Feeding Test (NSF): NSF is designed to evaluate the anxiolytic and/or antidepressant effects of chronic antidepressant drug treatment. The tester consists of a 50×50×20cm plastic box. During the test, after 48 hours of fasting and water deprivation, a weighed ordinary rat food pellet was placed on a white paper platform in the center of the plastic box. Each rat was placed in a corner of the box, and after the rat adapted for 1 minute, it was allowed to explore for up to 5 minutes. The test ended when the rat chewed a portion of the food. The amount of food consumed in the cage was taken as the amount of food consumed within 5 minutes. If there was no food at the end of the timing, it was calculated as 5 minutes, and the time when the rat first ate the food pellet was recorded as the latency.
2.6脑组织尼氏染色分析:在行为实验结束后禁食和缺水24小时,将3只大鼠处死后,冰面上迅速剥立大脑组织,并置于4%的多聚甲醛中固定15min,经脱水、包埋、切片制作石蜡切片,尼氏染色,观察拍照各组海马神经元的情况。其余大鼠在冰上从大脑中取出并迅速分离海马体,用液氮快速冷冻后,保存于-80℃备用。2.6 Analysis of brain tissue Nissl staining: After fasting and water deprivation for 24 hours after the behavioral experiment, three rats were killed, and the brain tissue was quickly peeled off on ice and fixed in 4% paraformaldehyde for 15 minutes. After dehydration, embedding, and slicing, paraffin sections were made, Nissl staining was performed, and the conditions of hippocampal neurons in each group were observed and photographed. The remaining rats were removed from the brain on ice and the hippocampus was quickly isolated, quickly frozen with liquid nitrogen, and stored at -80°C for later use.
2.7 Western blot法检测脑组织蛋白表达:把30μg蛋白质样品放在100V稳定电压下开始电泳,转移蛋白质到PVDF膜上。在室温震动台上把密封缓冲液(注:缓冲液为用TBSTBuffer稀释的5%脱脂牛奶,由武汉谷歌生物科技有限公司提供)放置两小时。添加BDNF(1:1000)、Trkb(1:1000)和CREB(1:1000)抗体。用Tris-hcl缓冲盐溶液冲洗10min×3次,加入辣根过氧化物酶标记二抗(1:10000)(注:二抗为HRP标记山羊抗兔),在37℃下反应1小时,冲洗10分钟、曝光3次后显影固定。使用天能GIS底盘控制软件V2.0测量带钢吸光度,并选择β-actin作为内部参考。2.7 Western blot method to detect brain tissue protein expression: 30μg protein sample was placed at a stable voltage of 100V to start electrophoresis and transfer the protein to the PVDF membrane. The sealing buffer (Note: the buffer is 5% skim milk diluted with TBSTBuffer, provided by Wuhan Google Biotechnology Co., Ltd.) was placed on a room temperature shaking table for two hours. BDNF (1:1000), Trkb (1:1000) and CREB (1:1000) antibodies were added. Rinse with Tris-hcl buffered saline for 10min×3 times, add horseradish peroxidase-labeled secondary antibody (1:10000) (Note: the secondary antibody is HRP-labeled goat anti-rabbit), react at 37℃ for 1 hour, rinse for 10 minutes, expose 3 times, and then develop and fix. The absorbance of the strip was measured using Tianneng GIS chassis control software V2.0, and β-actin was selected as the internal reference.
2.8统计学处理:使用统计软件Graph Pad Prism 9.0.0(86)进行统计学分析。所有组数据均采用单因素方差分析(ANOVA),并以平均值±标准差表示。P<0.05被认为具有统计学意义。2.8 Statistical analysis: Statistical analysis was performed using the statistical software Graph Pad Prism 9.0.0 (86). All group data were analyzed using one-way analysis of variance (ANOVA) and expressed as mean ± standard deviation. P < 0.05 was considered statistically significant.
3.实验结果3. Experimental results
3.1行为学检测结果:在成功建立CUMS大鼠模型35天后,进行SPT、FST和NSF行为学测试,测试结果如图10所示。3.1 Behavioral test results: 35 days after the successful establishment of the CUMS rat model, SPT, FST and NSF behavioral tests were performed. The test results are shown in Figure 10.
从图10可以看出,与对照组相比,模型组可显著降低大鼠糖水偏好,而灌胃0.02g/kg氟西汀和8.4g/kg、14g/kg中药膏可显著逆转大鼠糖水偏好的下降(图10A)。在大鼠NSF和FST中,与对照组相比,CUMS模型组大鼠静止时间明显延长(P<0.05),而氟西汀组和各剂量中药膏组大鼠的静止时间显著缩短(P<0.05)(图10B和图10C)。As can be seen from Figure 10, compared with the control group, the model group can significantly reduce the rats' preference for sugar water, while intragastric administration of 0.02g/kg fluoxetine and 8.4g/kg and 14g/kg Chinese medicine ointment can significantly reverse the decline in rats' preference for sugar water (Figure 10A). In the rat NSF and FST, compared with the control group, the immobility time of rats in the CUMS model group was significantly prolonged (P<0.05), while the immobility time of rats in the fluoxetine group and each dose of Chinese medicine ointment group was significantly shortened (P<0.05) (Figure 10B and Figure 10C).
3.2脑组织尼氏染色结果:脑组织尼氏染色结果如图11所示。从图11可以看出,与正常对照组相比,模型组神经元细胞排列稀疏,数量较少,部分核固缩,尼氏小体减少或消失。给予氟西汀和中、高剂量的中药膏后,神经元细胞排列变得规则,神经元细胞和尼氏小体数量增多,细胞形态基本恢复。3.2 Nissl staining results of brain tissue: The results of Nissl staining of brain tissue are shown in Figure 11. As can be seen from Figure 11, compared with the normal control group, the neuronal cells in the model group are sparsely arranged, the number is small, some of the nuclei are condensed, and the Nissl bodies are reduced or disappeared. After the administration of fluoxetine and medium and high doses of Chinese medicine ointment, the arrangement of neuronal cells became regular, the number of neuronal cells and Nissl bodies increased, and the cell morphology was basically restored.
3.3 Western blot蛋白表达分析结果:3.3 Western blot protein expression analysis results:
Western blot蛋白表达分析结果如图12、13所示,其中,图12为各组大鼠海马组织中BDNF、p-Trkb、p-AKT和p-CREB蛋白表达条带图,图13为各组大鼠海马组织中BDNF、p-TrkB、p-AKT和p-CREB蛋白表达量比较结果。The results of Western blot protein expression analysis are shown in Figures 12 and 13, where Figure 12 is a bar graph of BDNF, p-Trkb, p-AKT and p-CREB protein expression in the hippocampal tissues of rats in each group, and Figure 13 is a comparison of the expression levels of BDNF, p-TrkB, p-AKT and p-CREB proteins in the hippocampal tissues of rats in each group.
从图12、13可以看出,与对照组相比,模型组大鼠在持续慢性应激35天后,海马区BDNF蛋白表达及下游p-TrkB/TrkB、p-AKT/AKT、p-CREB/CREB比值显著降低(P<0.05)。与模型组比较,各给药组可显著提高大鼠海马组织BDNF的表达(P<0.05)。同时,连续给中药膏后显著抑制了大鼠海马的BDNF下游p-TrkB/TrkB、p-AKT/AKT和p-CREB/CREB比值的降低(P<0.05),而通过给予拮抗剂ANA-12干预后阻断了中药膏在海马中的这种作用(P<0.05),提示BDNF-TrkB信号传导通路有可能参与其抗抑郁作用机制。由于BDNF是海马与其他脑区之间突触传递和长期增强的重要神经调节因子,在维持海马神经元功能、促进神经元再生、抑制神经元凋亡等方面突出重要作用;TrkB受体与BDNF有高亲和力,跟BDNF特异性结合后,可同时激活下游MAPK、PI3K/Akt、cAMP等多条信号通路,参与并介导抑郁症的发生发展;同时,CREB已被证实与神经系统的可塑性有关。CREB被进一步激活,可促进突触空间神经递质的释放,干扰神经细胞的增殖和分化。因此表明中药膏的抗抑郁的作用机制可能与影响神经可塑性密切相关。As can be seen from Figures 12 and 13, compared with the control group, the expression of BDNF protein and the downstream p-TrkB/TrkB, p-AKT/AKT, and p-CREB/CREB ratios in the hippocampus of the model group rats were significantly reduced after 35 days of chronic stress (P<0.05). Compared with the model group, each drug-treated group significantly increased the expression of BDNF in the hippocampus of rats (P<0.05). At the same time, continuous administration of Chinese medicine ointment significantly inhibited the decrease of the BDNF downstream p-TrkB/TrkB, p-AKT/AKT, and p-CREB/CREB ratios in the hippocampus of rats (P<0.05), and the effect of Chinese medicine ointment in the hippocampus was blocked by the intervention of antagonist ANA-12 (P<0.05), suggesting that the BDNF-TrkB signaling pathway may be involved in its antidepressant mechanism. Since BDNF is an important neuromodulator of synaptic transmission and long-term potentiation between the hippocampus and other brain regions, it plays an important role in maintaining hippocampal neuron function, promoting neuron regeneration, and inhibiting neuron apoptosis. TrkB receptor has a high affinity with BDNF. After specific binding with BDNF, it can simultaneously activate multiple signaling pathways such as downstream MAPK, PI3K/Akt, and cAMP, and participate in and mediate the occurrence and development of depression. At the same time, CREB has been proven to be related to the plasticity of the nervous system. CREB is further activated, which can promote the release of neurotransmitters in the synaptic space and interfere with the proliferation and differentiation of nerve cells. Therefore, it shows that the anti-depressant mechanism of Chinese medicine ointment may be closely related to the influence on neural plasticity.
综上,本发明的中药组合物可以显著增加大鼠在SPT中的糖水偏爱程度,缩短大鼠在FST和NSF中的不动时间,同时可以减轻CUMS导致的抑郁症对大鼠脑组织造成的病理损伤,表明对抑郁症模型大鼠有较好的防治作用,其抗抑郁的作用机制可能与影响神经可塑性密切相关。In summary, the Chinese medicine composition of the present invention can significantly increase the preference for sugar water in rats in SPT, shorten the immobility time of rats in FST and NSF, and reduce the pathological damage of depression caused by CUMS to the brain tissue of rats, indicating that it has a good preventive and therapeutic effect on depression model rats, and its antidepressant mechanism may be closely related to the impact on neural plasticity.
以上所述的仅是本发明的一些实施方式。对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.
Claims (9)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2024101400804 | 2024-01-31 | ||
CN202410140080 | 2024-01-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118059206A true CN118059206A (en) | 2024-05-24 |
CN118059206B CN118059206B (en) | 2025-04-08 |
Family
ID=
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101919924A (en) * | 2010-05-07 | 2010-12-22 | 广东药学院 | A kind of pharmaceutical composition for treating depression and its preparation method and application |
CN104274794A (en) * | 2013-07-08 | 2015-01-14 | 广东省中医院 | Nerve-soothing mind-tranquilizing paste and preparation method |
CN114588243A (en) * | 2021-05-11 | 2022-06-07 | 胡号应 | Formula of two alternately taken traditional Chinese medicines for treating depression and anxiety |
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101919924A (en) * | 2010-05-07 | 2010-12-22 | 广东药学院 | A kind of pharmaceutical composition for treating depression and its preparation method and application |
CN104274794A (en) * | 2013-07-08 | 2015-01-14 | 广东省中医院 | Nerve-soothing mind-tranquilizing paste and preparation method |
CN114588243A (en) * | 2021-05-11 | 2022-06-07 | 胡号应 | Formula of two alternately taken traditional Chinese medicines for treating depression and anxiety |
Non-Patent Citations (2)
Title |
---|
王斐 等: "赵杰从阳虚辨治抑郁症经验", 山东中医杂志, vol. 39, no. 05, 5 May 2020 (2020-05-05), pages 500 - 503 * |
金涛: "抑郁、焦虑症中医治疗的进展", 浙江中医药大学学报, vol. 31, no. 04, 15 July 2007 (2007-07-15), pages 526 - 527 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1753682A (en) | Herbal composition for prostate disease | |
CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
US6596321B1 (en) | Pharmaceutical composition for treating angiocardiopathy and the method of producing thereof | |
CN107853517A (en) | A kind of antifatigue Chinese medicinal drink and preparation method thereof of refreshing oneself | |
CN100427136C (en) | A kind of pharmaceutical composition for treating fatty liver and its preparation method and application | |
CN110664906A (en) | Preparation method of health food with blood sugar reducing function | |
CN118059206A (en) | Antidepressant traditional Chinese medicine composition and preparation method and application thereof | |
CN115414435B (en) | Chinese herbal compound Ge Houdan poria cocos granule and preparation method and application thereof | |
CN115252753B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
CN113813335B (en) | Traditional Chinese medicine composition for treating radiation injury and preparation method thereof | |
CN115887568A (en) | A traditional Chinese medicine composition for treating liver damage caused by lipid metabolism disorder and preparation method thereof | |
CN108478714A (en) | A kind of paediatrics self-closing disease rehabilitation auxiliary Chinese medicine composition | |
TWI721367B (en) | Composition for regulating endocrine, improving immunity, delaying aging and preventing or treating constipation, its application and preparation method thereof | |
CN115919927B (en) | Traditional Chinese medicine composition and application thereof | |
CN115779023B (en) | Traditional Chinese medicine composition for treating stomachache and preparation method and application thereof | |
CN115245549B (en) | A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis | |
CN114848781B (en) | A Chinese medicinal composition for treating bradyarrhythmia and preparation method thereof | |
CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
CN103948754A (en) | Drug for treating renal-deficiency humid-heat type chronic nephritis | |
Nesari et al. | Fenugreek (Methika): Traditional Wisdom and Research Evidences | |
CN117942359A (en) | Health care product for assisting in improving perimenopausal syndrome and preparation method thereof | |
CN117137999A (en) | A traditional Chinese medicine composition with the effect of reducing weight, lowering blood sugar and lowering lipids, its preparation method and application | |
CN101264202B (en) | Hericium erinaceus digestion-promoting Chinese medicinal composition and preparation thereof | |
CN106362100A (en) | Traditional-Chinese-medicine compound preparation for treating damaged function of islet of 2-type diabetes mellitus and preparation method thereof | |
CN105535429A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |